Sygnature Discovery expands US presence with Bay Area office

Sygnature Discovery has established a new office presence in South San Francisco’s biotech hub at Oyster Point, to get closer to and better serve current and future clients on the US west coast.

The new office comes in the wake of another year of impressive growth for Sygnature, having recently expanded operations at our headquarters in Nottingham, UK, as well as opening a second co-located integrated drug discovery site on the world-class research campus at Alderley Park, UK.

We established our first US office in 2019 in the heart of the Cambridge–Boston biotech hub in Massachusetts, and this expansion of our US presence with a second office will help meet growing demand from our US customers, which range from major pharma through to small seed-funded biotechs.

“Our very first client was actually from the US,” said Simon Hirst, Sygnature’s CEO and founder, “and it remains a very significant market for us, both now and in our future strategy. It’s fantastic to have a base on the west coast, and in such a vibrant hub for the life sciences community.

“Our approach to drug discovery is based on true collaboration and partnership with our clients, and having a physical presence near to many of them helps us to work the way we believe in – strengthening those ties and relationships that lead to success.”


The new office is located on Gateway Boulevard, Oyster Point, in South San Francisco – often nicknamed “the Birthplace of Biotechnology” and home to one of the largest biotech clusters in the world, with over 200 biotech companies, and 11.5 million square feet of biotech space across 500 acres.

So, if you are based in the Bay Area or happen to be visiting, please let us know if you would like to pop in for a visit. And  of course you can always get in touch with us via our contact forms.

Latest News

View All

Sygnature Discovery Receives EcoVadis Award For Sustainable…

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…